MetaVia Inc. (MTVA)

In early December 2025, MetaVia announced and effected a 1-for-11 reverse stock split of its common stock to address Nasdaq's minimum bid price requirement. In January 2026, MetaVia completed a public offering that raised $9.3 million, which is expected to fund operations into the fourth quarter of 2026. In January 2026, the company announced positive statistically significant results from the Phase 1 clinical trial of DA-1726. In March 2026, MetaVia expanded global patent protection for vanoglipel through 2035. On March 26, 2026, MetaVia reported its year-end 2025 financial results, showing a net loss of $13.0 million. In March 2026, MetaVia advanced its GLP-1-based obesity program with IRB approval for higher-dose Phase 1 studies of DA-1726. Over the past 12 months, the stock has experienced a significant decline, losing approximately 92.9%.

As a clinical-stage biopharmaceutical company, MetaVia, Inc. does not currently have commercially marketed products and therefore does not experience traditional demand seasonality. Its demand is primarily driven by investor interest, progress in its clinical trials, regulatory milestones, and the overall outlook for its drug candidates in the cardiometabolic disease market.

MetaVia, Inc. is a clinical-stage biopharmaceutical company focused on developing novel pharmaceuticals for cardiometabolic diseases, including obesity and associated disorders. Formerly known as NeuroBo Pharmaceuticals, Inc., MetaVia rebranded in November 2024, shifting its focus from oncology to metabolic diseases. The company's primary products are investigational drug candidates DA-1726, a novel oxyntomodulin analogue, and Vanoglipel, a novel G-Protein-Coupled Receptor 119 agonist. MetaVia's business model is centered on research and development, and it does not currently generate product revenue.

MetaVia is headquartered in the United States, with corporate offices historically in California and currently in Cambridge, Massachusetts. Its operational footprint is primarily domestic, with international activities limited to the use of global clinical research organizations and trial sites outside the U.S. for clinical development.

MetaVia's brand reputation has likely been positively influenced by its clinical advancements and strategic focus. The announcement of promising results from the Phase 1 trial of DA-1726 enhances the company's scientific credibility. Securing global patent protection for vanoglipel through 2035 reinforces the company's intellectual property. The company's shift to focus on metabolic diseases could be viewed positively by the scientific and investment communities.

Major institutional owners include Vanguard Group Inc, Citadel Advisors Llc, Morgan Stanley, UBS Group AG, BlackRock, Inc., Tower Research Capital LLC (TRC), SBI Securities Co., Ltd., Jpmorgan Chase & Co, Bank Of America Corp /de/, Brown Brothers Harriman & Co, SG Americas Securities LLC, and Virtu Financial LLC, owning approximately 1.37% of MetaVia's stock. Dong-A ST Co., Ltd. holds a significant stake of 55.06% in MetaVia Inc.